H.A.L.T. MAX Spectacle Lenses for High Myopia Control
Clinical Study on Efficacy and Safety of H.A.L.T. MAX Spectacle Lenses for High Myopia Control in Children and Adolescents
This study is intended to focus on children aged 7-14 years with high myopia and to use a 2-year, single-arm, prospective design in which participants wear H.A.L.T. MAX lenses for at least 12 hours per day for 2 consecutive years. By comparing changes in refractive error and other indicators, the study will evaluate the efficacy, safety, and wearing compliance of H.A.L.T. MAX lenses in delaying myopia progression in children with high myopia, thereby providing scientific evidence for public health efforts to delay myopia progression in highly myopic populations and for the formulation and implementation of programs to address the risk of blindness and visual impairment caused by high myopia.
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- 7-14 years old, regardless of gender.
- Spherical equivalent refraction (SER) after cycloplegia ≤ -5.00 D and ≥ -9.00D.
- Best corrected visual acuity in both eyes reached 0.8 (0.10 logMAR 6/7.5).
- Anisometropia and astigmatism value ≤ 2.5 D.
- Willing to wear only the spectacles provided by the investigator for a full day (>12 hours) without additional intervention during the study.
- Able to sign the informed consent with the presence of parents or guardians.
Exclusion Criteria:
- Allergic or intolerant to cycloplegic drugs.
- Exclude children on high dose atropine (1%) or red light therapy.
- Any previous history of myopia control treatment in the previous 30 days, like low dose atropine, defocus spectacles, orthokeratology and acupuncture.
- History or presence of an ocular disease, strabismus or amblyopia or other binocular vision abnormalities, accommodation dysfunction, and cataract.
- History of eye surgery.
- Eye or systemic diseases that may be associated with myopia, such as Marfan syndrome, retinopathy of newborns, diabetes, etc.
- Anatomic or skin factors affecting the wearing of spectacles.
- Other conditions unsuitable for inclusion (patients with excessive expectations for the effect of the defocus spectacle lenses or desires to try other myopia interventions).
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Intervention Group
Wearing H.A.L.T. MAX spectacles for at least 12 hours a day over 2 years. |
Wearing H.A.L.T. MAX spectacles for at least 12 hours a day over 2 years. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
SER change
大体时间:2 years
|
The proportion of of the right eye SER change ≤ -1.50D after 2 year of intervention. |
2 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Axial change
大体时间:2 years
|
The proportion of the right eye axial change ≥ 0.68 mm after 2 year of intervention. |
2 years
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Visual quality
大体时间:2 years
|
Visual aquity |
2 years
|
|
Adaptation outcome
大体时间:2 years
|
Daily spectacles wearing time |
2 years
|
|
Safety outcome
大体时间:2 years
|
Occurrence of adverse events |
2 years
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- WS104222026
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.